Multinational phase 1 study of avelumab, palbociclib, and axitinib for advanced NSCLC
Dr. Benjamin Solomon
The multinational phase 1 SPRING study by the Worldwide Innovative Network Consortium evaluated triplet therapy with avelumab, palbociclib, and axitinib for previously treated advanced NSCLC without EGFR, ALK, or ROS1 alterations. The study found partial response in 4 of 15 patients (27%; PFS 14, 24, 25 and 144+ weeks) including two after progression on pembrolizumab. Four other patients attained stable disease lasting 24, 27, 29, and 64 weeks. The recommended phase 2 dose was well tolerated.
